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Abstract 
Despite a lack of recent progress in the treatment of schizophrenia, our understanding of its genetic 
and environmental causes has considerably improved, and their relationship to aberrant patterns of 
neurodevelopment has become clearer. This raises the possibility that “disease-modifying” strategies 
could modify the course to - and of - this debilitating disorder, rather than simply alleviating 
symptoms. A promising window for course-altering intervention is around the time of conversion, 
especially in young people vulnerable to transition. Indeed, studies performed both in subjects at risk 
and in rodent models for schizophrenia suggest that pre-diagnostic pharmacotherapy and/or 
psychosocial/cognitive-behavioural interventions can delay and/or moderate the emergence of 
psychosis. Of particular interest are “hybrid” strategies that both relieve presenting symptoms and 
reduce the risk of transition to schizophrenia - or another psychiatric disorder. This is an opportune 
moment for a broad-based consideration of the challenges and opportunities inherent in efforts to alter 
the course of schizophrenia.  
 
 
Abbreviations: APS, Attenuated Psychotic Symptoms; BDNF, Brain-derived Neurotropic Factor; 
CBT, Cognitive-Behavioural therapy;  CHR, Clinically High Risk; CRF, Corticotrophin Releasing 
Factor; DISC, Disrupted in Schizophrenia; ERP, Event-Related Potential; FEP, First Episode of 
Psychosis; fMRI, functional Magnetic Resonance Imaging; HDAC, Histone deacetylase; HPA, 
Hypothalamo-Pituitary-Adrenal; iPSC, induced pluripotent stem cell; mGluR; metabotropic glutamate 
receptor; MMN, Mismatch Negativity; NAPLS, North American Prodrome Longitudinal Study; 
NKCC, Na-K-Cl co-transporter; NMDA, N-Methyl-D-Aspartate; PAM, positive allosteric modulator; 
PFC, Prefrontal cortex; Poly I:C, Polyriboinosinic:Polyribocytidylic; PUFA, Polyunsaturated fatty 
acid; SGA, Second Generation Antipsychotic and VHL, Ventrohippocamal lesion. 
 
 
 
 
Glossary entries are indicated as such in text. 
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Schizophrenia: clinical features and limitations of current treatment  
 Schizophrenia is a chronic, heterogeneous, multi-faceted and debilitating disorder triggered by 
a panoply of interacting genetic, epigenetic, developmental and environmental factors which 
collectively interfere with normal brain development and maturation1,2 (Figure 1). It has a prevalence 
of around 1% and represents a major socio-economic burden, mainly as a result of indirect costs like 
unemployment and social support, but also due to hospitalisation during crises1,3,4. Notwithstanding 
rare and usually severe cases of early-onset  schizophrenia, it is usually diagnosed in the young adult 
with the “First Episode of Psychosis (FEP)2-5 (Box 1). 
 Antipsychotics are effective against positive symptoms, yet some patients respond only poorly 
to treatment. Further, while clozapine remains the most effective agent for “resistant” patients, it has 
marked haematological and metabolic side-effects, and neither clozapine nor second-generation 
antipsychotics (SGA) like risperidone, olanzapine and aripiprazole markedly improve negative 
symptoms, neurocognitive deficits and impaired social processing/cognition. Thus, while the 
importance of currently-available treatments must be recognised, and there has been considerable 
progress in moderating their side-effects, there remains a clear unmet need for greater clinical 
efficacy6-8. Recently-evaluated glutamatergic agents have not yet proven sufficiently effective for 
authorisation9,10. Further, numerous mechanisms pursued as “add-ons” have met with limited success, 
possibly since SGAs undermine their ability to relieve cognitive impairment, and as most studies were 
undertaken in chronically-ill patients11,12. Improving the symptomatic treatment of schizophrenia 
remains an important goal, but progress will likely require a strategic shift in thinking (Suppl Figure 
1).  
By definition, symptomatic treatment does not affect the causes, pathophysiology and course 
of schizophrenia. On the other hand, an improved understanding of the neurobiological substrates of 
schizophrenia is fostering the notion that its evolution might be modified by novel modes of 
intervention, especially if instituted at an early stage of the disorder13-17. The challenges and 
opportunities inherent in the realisation of this goal comprise the central themes of this article.  
 
Course-alteration: general principles and application to schizophrenia  
Disease-modification as a therapeutic concept 
The notion of early, pre-diagnostic disease-modification (Figure 2) has its origins in medical 
domains like diabetes, oncology and rheumatoid arthritis, with efforts to develop preventative 
therapies for multiple sclerosis, Alzheimer’s disease and Parkinson disease intensifying over the past 
decade18-20. The more recent application of disease-modification to psychiatric states is highlighted by 
experimental evidence that developmental anomalies and behavioural deficits characterising 
(monogenic) autism-related disorders may be, at least partially, correctible21. These observations 
underscore interest in preventive treatment for bipolar depression22 and schizophrenia, not least since 
4 
 
NRDD CA RESUBMITTED TEXT GLOSS REFS LEGENDS 21 10 2015 s 
they are communalities with autism including: symptoms (cognitive and social impairment)12,21, 
genetic risk factors (single genes and Copy Number Variants)23,24, epigenetic anomalies (DNA and 
histone marking)25,26, environmental triggers (perinatal infection and inflammation)27,28 and 
neurobiological substrates (disruption of synaptic plasticity and cerebral connectivity)21,29,30.  That 
certain core features are shared between schizophrenia and other disorders is significant since it 
implies that course-altering strategies for blocking the onset of psychosis might be of broader 
therapeutic utility1,23,31-33.  
 
Course-alteration for schizophrenia: core questions  
Disease-modification refers to interventions that directly target the pathophysiological 
processes causing a disorder in a manner that enduringly modifies its progression19, but it is important 
to clarify its operational meaning as applied to schizophrenia. As depicted in Figure 2, it would seem 
wise to favour a broader and more pragmatic notion of course-alteration as a framework for study and 
therapeutics. Despite several characteristic neurodevelopmental anomalies, no common upstream 
trigger for schizophrenia is known1,2,29,30. Hence, course-alteration might target a plurality of 
mechanisms, acting in series and in parallel, and either aggravating or counteracting core 
pathophysiological substrates. Targetable pathological processes may differ between specific clinical 
dimensions: for example, avolition versus hallucinations versus impaired social cognition1,12-14,16,33.  
The initial diagnosis comes relatively late in the neurodevelopmental trajectory of 
schizophrenia, usually around 25 years of age, and antipsychotic treatment does not normally begin 
until this FEP. However, course-altering therapy is most likely to succeed when applied early. This is 
supported by evidence that marked and progressive anomalies in brain structure, neurochemistry and 
“connectivity” are already present by the time of diagnosis30,34-36. Precocious course-altering therapy 
for schizophrenia also makes sense in terms of potential cost-effectiveness37. Hence, despite potential 
intervention following the FEP (evoked later), the major focus is currently on prevention.  
A preventative approach to course-alteration raises several important questions. First, what is 
the optimal strategy for identifying people at risk of developing schizophrenia, and whom should be 
treated? Second, which therapeutic strategies would be the most effective for preventing the onset of 
schizophrenia and/or interfering with its progression? Third, how can the efficacy of course-altering 
treatments be clinically evaluated and proven? Fourth, is it possible to unite the treatment of 
symptoms seen in clinically-high risk (CHR) subjects with a reduction in the risk of transition? Indeed, 
might the control of anomalies and dysfunction in CHR patients of itself impede the onset of 
schizophrenia? 
Though currently-used antipsychotics may “stabilise” patients, this is essentially due to 
symptomatic effects expressed during treatment. Hence, a basic tenet of the following discussion is the 
need to identity novel and genuine course-altering therapies. To realise this objective, a broad suite 
of strategies is being deployed from cellular studies to therapeutic trials in subjects vulnerable to 
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schizophrenia. Accordingly, the discussion is structured around three complementary 
hierarchies of evidence, commencing with the most advanced and direct: A), clinical trials in 
high-risk, help-seeking subjects of pharmacotherapeutic and other interventions for preventing 
transition to psychosis; B), experimental evaluation of pharmacological agents for blocking the 
adult appearance of a “psychosis-like” phenotype in rodent models for schizophrenia C), 
cellular and in vivo studies of pathophysiological mechanisms implicated in events leading to the 
onset of psychosis.  
 
Young people at clinically-high risk of schizophrenia  
The clinically high-risk state  
Mental health problems are highly prevalent in the young, underpinning efforts to set up 
nationwide structures for their treatment and detection of subjects at risk of psychosis and other 
psychiatric disorders (Box 2).  Schizophrenia itself strikes the young adult in the wake of exposure to 
multiple risk factors from conception to adolescence23,24,27,38 (Figure 1A). Its onset is preceded by a 
phase (prodrome) during which several (sub-diagnostic) features progressively emerge, though with 
inter-individual differences. In line with the notion of clinical staging39, the earliest symptoms may be 
non-specific and include anxiety, depressed mood, social withdrawal and educational difficulties, 
followed by the emergence of “basic symptoms” (subtle disturbances of cognition, perception, 
language and emotion) and reduced stress tolerance/coping40,41. Later, more pronounced abnormalities 
and disorganised speech become apparent, as well as sub-diagnostic positive symptoms. These “Brief 
Limited Intermittent Psychotic Symptoms” and “Attenuated Psychotic Symptoms” (APS) are less 
severe than a fully-fledged psychotic episode35,42 (Box 1). During the prodromal period, both negative 
symptoms and impairment of social cognition are present: they are often marked and linked to poor 
functioning and a high likelihood of conversion8,12,40,43,44.  Neurocognitive deficits are also 
prominent12,40,43. 
 
Contrasting fates of CHR subjects at risk of transition to schizophrenia  
The notion of pre-diagnostic disease-modification presupposes the reliable identification of 
subjects at risk. While the term “prodrome” implies that schizophrenia is ineluctable, this is not 
actually the case. In fact, only a minority of people displaying a CHR state will develop schizophrenia 
or another psychotic disorder15,17,34,35,40,45 (Figure 3A). Meta-analyses suggest that the proportion is 
around 30%, but the percentage varies across samples. This variability reflects contrasting criteria of 
selection of CHR subjects for study, socio-demographic differences, environmental factors, coping, 
and varying degrees of clinical/family care and support14,34,35,38,40,46,47. The latter point supports the 
“hybrid” notion that treatment of CHR subjects may reduce the risk of conversion (see below). 
Nonetheless, complete recovery is rare, certain people persist in a state of impaired overall 
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functioning, and many develop other psychiatric disorders like depression or anxiety (Figure 3A). 
Hence, the need for preventive course-altering therapy remains persuasive, and all these individuals 
require treatment and specialized care17,32,34,35 (Box 2). 
 
Neurobiological characteristics of the CHR state: biomarkers of transition 
Clinical indices of impending conversion  
Although all CHR people may potentially transit to schizophrenia, certain features are 
associated with a particularly high risk of conversion. These include unusual thought content, marked 
impairment of verbal learning and memory, suspiciousness and paranoid ideation (especially when 
enduring and denied), low IQ, substance abuse, migrant status, isolation, poor quality of life and 
comorbidity with other disorders32,34,35,40,43,45,48. Inspection of CHR subjects may also unveil 
neurological “soft signs”: that is, motor and sensory changes provoked by neurodevelopmental 
abnormalities distributed across widespread cortical regions49,50. 
Such clinical observations are important for assessing vulnerability to psychosis, especially 
when coupled to information on life-style such as excessive consumption of cannabis38,51. Nonetheless, 
they are insufficient alone for either predicting the likelihood of transition at the individual level, or 
for stratifying subgroups of CHR subjects. Accordingly, more refined strategies for estimating the risk 
of conversion are being developed. Such measures of pathophysiological anomalies also provide 
insights into potential targets for course-altering medication13,16,35,48,52 (Figure 3B).  
 
Genetic profile: risk genes and gene “networks”  
The genetics of schizophrenia are complex with: 1), a few, very rare variants of large effect vs 
innumerable variants of very small and collective impact: 2), a role for rare Copy Number Variants 
encompassing multiple genes and stretches of DNA and 3), both inherited and de novo anomalies23,24 
(Suppl Box 1). Nonetheless, Neurexin-1 has been consistently linked to schizophrenia, the risk 
gene Neuregulin1 was specifically associated with a high risk of transition, and gene clusters, 
pathways and interactions (“epistasis”) may yield associations more robust than for individual 
genes53,54,55. Thus, no universal genetic biomarker of the risk of transition is currently available, 
but useful readouts may soon emerge. Moreover, a family history of psychosis can be readily 
factored into estimations of risk, as undertaken by the North American Prodrome Longitudinal Studies 
(NAPLS) Consortium and the European Prediction of Psychosis study34,43,48. 
 
Biochemical and endocrine measures in the circulation  
Increases in leucocyte levels of Interleukin-6 (a pro-inflammatory cytokine) and decreases in 
Brain-Derived Neurotrophic Factor (BDNF) are correlated with a reduced volume of the hippocampus 
in FEP, measures being extended to the CHR state56. Further, high plasma levels of pro-inflammatory 
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cytokines correlated with a steep decline of prefrontal cortex (PFC) grey matter in CHR subjects that 
progressed to psychosis57. More generally, the risk of transition may be associated with a specific 
molecular signature in blood involving immune-inflammatory biomarkers58-60. Another 
promising approach focusses on epigenetic readouts, such as patterns of DNA methylation and 
miRNA profiles in lymphocytes26,61,62.   
Reflecting increased exposure and/or sensitivity to psychosocial stress, altered activity of the 
Hypothalamic-Pituitary-Adrenocorticotrophic (HPA) Axis is common in the CHR state and suggestive 
of a high risk of conversion: further, HPA axis over-activity is correlated with hippocampal volume 
loss63,64. Though the specificity of stress-related HPA hyper-activation to risk for schizophrenia is 
debatable, converters had higher salivary cortisol in the NAPLS study48,63. Further, increased 
circulating cortisol is linked to excessive striatal release of DA and positive symptoms both in CHR 
subjects and in people with familial high risk63,65,66. It is also related to poor stress-coping, anxiety and 
suspiciousness, psychological factors themselves associated with conversion34,35,40,67.  
 
Structural and functional imaging: neurotransmitters and neural circuits  
As quantified by Magnetic Resonance Spectroscopy, schizophrenia is associated with altered 
glutamatergic transmission in several brain regions, and abnormalities are already evident in CHR 
subjects68,69. Changes include increases in glutamate in the associative striatum, reductions in the 
thalamus, and an uncoupling of glutamate levels from functional activation of the medial temporal 
cortex during an episodic memory task68,69. Further, a prodromal hyper-metabolic state of the 
hippocampus, mimicked in an animal model, was attributed to excess glutamate release: it was 
associated with GABAergic interneurone dysfunction, neuronal atrophy and spreading to the 
subiculum upon onset of psychosis70. In the CHR state, changes in glutamatergic transmission 
originating in the cortex appear to drive alterations in subcortical dopaminergic transmission71,72. They 
are exemplified by an increase in the presynaptic synthesis and storage of subcortical DA, 
especially in the associative striatum, which becomes progressively more pronounced as subjects 
move to psychosis72,73. DA depletion studies have linked this increased DA availability to greater 
occupation of postsynaptic D2 receptors72-74. On a different tack, reduced levels of the marker of 
neuronal integrity, N-acetyl-aspartate, in frontocortico-cingulate cortex may be indicative of 
susceptibility to transition, with decreases intensifying upon diagnosis75.  
Loss of grey matter volume coupled to increased lateral ventricle size is highly reproducible in 
schizophrenia and Magnetic Resonance Imaging (MRI) of progressive structural changes in CHR 
subjects can reveal a risk of transition. Indeed, mirroring grey matter loss in drug-naïve FEP patients, 
CHR subjects display reductions in grey matter in para-hippocampal territories, the cerebellum, the 
superior/medial temporal cortex, the insular cortex and the PFC8,57,76-78. Progression of CHR subjects 
through various premorbid stages and conversion correlates with incremental grey matter loss39,73,79. 
8 
 
NRDD CA RESUBMITTED TEXT GLOSS REFS LEGENDS 21 10 2015 s 
The precise pattern may even predict the type of psychosis since reductions in PFC/parietal cortex and 
PFC/subgenual cingulate cortex were linked to schizophrenia and affective psychosis, respectively80.  
Functional MRI (fMRI) of cerebral circuits is likewise instructive36. For example, altered 
activity in cortico-striatal pathways correlated to an APS in the prodromal period81 and parallels the 
above-mentioned enhancement of presynaptic dopaminergic activity in the associative striatum72,73. 
Further, suppression of the dorsolateral PFC component of the Default Mode Network during a 
Working Memory task was blunted both in early schizophrenia and in CHR groups82. Deficient 
Working Memory in vulnerable subjects has also been related to aberrant coupling of the PFC to the 
parietal cortex83. Finally, altered activity of fronto-temporo-parietal regions has been linked to 
negative and social cognitive symptoms8. 
To summarize: alterations in dopaminergic, glutamatergic and GABAergic 
transmission; loss of gray matter in discrete cortico-limbic regions; and disruption of network 
connectivity are anomalies that parallel the progressive onset of psychosis (Figure 1). 
Collectively, they provide a broad suite of imaging readouts for estimating the risk of psychosis.  
 
 
Electroencephalographical readouts: event-related potentials 
Electroencephalographic probing of large-scale brain networks can reveal anomalies in 
cerebral connectivity, neural synchrony and the balance of inhibition/excitation. Accordingly, it is 
potentially useful for assessing the risk of transition84,85. In addition, studies of event-related potentials 
(ERPs) have shown that two responses to deviant stimuli, one positive (P300) and one negative 
(Mismatch Negativity, MMN) are modified in schizophrenia and in CHR subjects33,86-88. Both 
responses have a strong glutamatergic component and are disrupted by the N-Methyl-D-Asparate 
(NMDA) receptor antagonist and pro-psychotic agent, ketamine87-89. The attenuation of P300 in CHR 
subjects that subsequently convert has been related to disruption of grey (and white) matter in 
temporo-parietal cortex and the frontal gyrus, regions implicated in cognitive deficits, impaired 
language processing and negative symptoms8,86,90. Importantly, perturbation of duration-deviant 
MMN is specific to schizophrenia, and its amplitude is reproducibly blunted in the 
prodrome87,88,91. In longitudinal studies, the amplitude of MMN permitted sub-division of 
patients into higher and lower risk groups88,91. Further, meta-analyses suggest that MMN 
perturbation is the most consistent ERP biomarker of conversion and may be exploitable in a 
prospective fashion to predict which CHR subjects will convert, with a greater magnitude of 
reduction correlated to more imminent onset of psychosis87,88,91. Another advantage of MMN is 
its translational dimension inasmuch as neurobiological substrates are common to animals and 
humans, and disruption can be measured using similar methods87-89,91.  
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Towards the stratification of subjects at risk of transition  
By analogy to efforts to better classify sub-classes of patient33, a major current goal is the 
sub-categorisation of CHR subjects as defined by individual or suites of biomarkers, preferably 
linked to a targetable neurobiological anomaly. This should improve the prediction of transition, 
reduce group heterogeneity and enhance the power and rigour of clinical trials (see below). 
Despite limitations of genetics (Suppl. Box 1), deletion of the synaptic protein Neurexin-1 may 
define a subset of subjects at risk52,92, and subgroups may also be revealed by analysis of gene 
networks54. Another potential approach for stratification sub-classifying CHR subjects is a 
disruption of MMN88,91 and, when coupled to MMN, deficits, cognitive dysfunction may be 
particularly informative93,94. The pattern of grey matter loss also differs between phenotypically-
distinct patient subgroups80. Finally, blood-borne palettes of immune and other biochemical 
markers have been proposed for at-risk subject sub-classification59.  
 
Multi-modal strategies for more reliable prediction of conversion in individuals 
Irrespective of group means, it is imperative to accurately predict the risk of transition to 
schizophrenia in individuals with as few false positives (stigma, superfluous treatment, costs etc) and 
false negatives (failure to protect) as possible. It is unlikely that any single readout would be fully 
reliable, specific and of universal utility. Correspondingly, multi-modal strategies are the focus of 
several ongoing studies34,52,83.  For example, the NAPLS Consortium has developed a plasma-based, 
multi-parametric diagnostic predictive of transition that incorporates excess cortisol secretion, as well 
as markers of inflammation, oxidative stress and metabolic anomalies60. A similar approach 
suggested the high predictive performance of an optimised panel of >20 blood protein 
biomarkers in parallel with patient interviews59. By analogy, a combination of genetic risk, 
asociality, functional impairment, negative symptoms and/or APS was associated with a particularly 
high risk of psychosis48. Another instance is the coupling of “basic cognitive symptoms” and standard 
CHR criteria to improve early detection94. Patterns of polygenic risk can be linked to fMRI-
documented alterations in cerebral activity95, while convergent (fMRI) and structural (MRI/grey 
matter and Diffusion Tensor Imaging/white matter) readouts suggest that superior temporal cortex 
disruption may be a strong warning sign8,96. Finally, machine-learning and other multivariate 
techniques for deciphering complex patterns of data are being developed to refine estimations of the 
risk of transition in single subjects97,98.  
Overall, multi-modal strategies seem promising both for: 1), improving predictions at 
the individual level and 2), characterising sub-populations of patient at differential risk of 
transition and possessing contrasting neurobiological substrates for intervention.  
 
10 
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Clinical studies of course-altering interventions in CHR subjects  
Therapeutic trials for preventing transition  
 Despite the challenges, and a lack of formal guidelines, several controlled, clinical trials in 
CHR subjects have addressed the issue of whether the rate and time of conversion can be influenced 
by potential course-altering therapy15,16,34 (Table 1). Studies focussing on transition have been 
performed with: Omega-3 poly-unsaturated fatty acids (PUFA)99,100 ; antipsychotics101; antipsychotics 
in combination with cognitive-behavioural  therapy  (CBT)102-104; and various modes of non-
pharmacotherapeutic intervention alone105-109. Several, independent meta-analyses have concluded 
that: robust clinical trials in help-seeking CHR subjects are feasible; treatment is associated with a 
significant, overall increase in the time to transition and a decrease in the numbers of patients 
converting34,110,111. However, whether transition is merely delayed and/or permanently halted remains 
to be clarified. Further, since trials undertaken to date were modest in size, larger-scale, higher-
powered studies are required to confirm observations, refine tools for assessment and outcome 
analysis, and evaluate the significance of additional factors like gender and co-morbidity (see 
below)34,110-113.  
 
Omega-3 and poly-unsaturated fatty acids 
Despite the ambivalent efficacy of Omega-3 in established schizophrenia, levels of PUFAs are 
reduced boht in diagnosed patients and in CHR subjects, supporting interest in trials of preventative 
treatment114,115. In a focussed study, the decreased conversion in CHR subjects treated with Omega-3 
PUFAs (eicosapentaenoic acid, 700 mg/day plus docosahexaenoic acid, 480 mg/day) was maintained 
for a year despite only 3 months treatment, and tolerance was excellent99,100,116.  Patient function, 
together with both positive and negative symptoms, was improved. (Interestingly, those subjects with 
Borderline Personality Disorder were similarly ameliorated upon treatment with Omega-3117). 
Longer-term findings have just been reported at 6.7 years with better functioning, a persistent 
reduction in transition to schizophrenia, and a more general decrease in psychiatric 
morbidity118. However, this was a modest sample size, and another study of Omega-3 was less 
positive in its outcome119 (McGorry, P, pers comm.). Thus, course-altering effects of Omega-3 
may depend upon the precise regime and conditions of treatment, and further trials are needed 
to confirm its potential utility, possibly in distinct subgroups of patient. Moreover, whether 
preventive effects of Omega-3 are specific to psychosis remains to be established120. Finally, for 
future progress, it will be important to better understand how Omega-3 exerts its effects, since a 
multiplicity of mechanisms has been implicated including: anti-inflammatory and anti-oxidant 
properties; improved membrane fluidity, mitochondrial performance and synaptic plasticity; inhibition 
of Phospholipase A2; normalisation of under/over-active mesocortical/mesolimbic dopaminergic 
11 
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pathways; promotion of white matter integrity and restoration of adequate levels of nervonic acid, a 
major component of the myelin sheath100,121,122.  
 
Second-generation antipsychotics  
In the “PRIME” study of olanzapine, 11 of 29 subjects converted to psychosis on placebo 
compared to 5 of 31 on medication, but the difference was not significant101. In the olanzapine 
group, psychosis always occurred in the first four weeks when doses were relatively low, so it 
may not have had sufficient opportunity to act effectively101. Interestingly, by week eight, 
prodromal symptoms were significantly lower on olanzapine compared to placebo, but weight 
gain was marked: 8.8 kg vs 0.3 kg101. Globally similar observations on transition were made 
when risperidone was combined with CBT/needs-based interventions or cognitive 
therapy102,104,123. In the “PACE” 1 study, despite reduced conversion at 6 months for risperidone 
(3/31) vs placebo (10/28), the difference was no longer significant at 12 months . In the “PACE” 
II study, conversion also did not differ, and all groups demonstrated improvement in symptoms 
and functioning103. 
Thus, to date, there is no clear evidence that antipsychotics can prevent transition (Table 1).  
Further, despite relief of sub-diagnostic psychosis in CHR subjects and the fact that risperidone was 
relatively well-tolerated, CHR subjects are especially susceptible to side-effects like metabolic 
perturbation and sedation/fatigue1632,34,35,102-104. In practise, many young people will not accept 
antipsychotics owing to concerns about adverse effects and stigmatisation, and they are not 
recommended by many National Guidelines for CHR subjects.17,32,34,35,110,111,113.  More generally, 
there is concern about over-prescription of antipsychotics to youth for reasons other than the 
control of psychosis124. Nonetheless, additional prevention studies with new agents appear 
warranted. In an open study of the partial D2 receptor agonist, aripiprazole, it improved 
prodromal symptoms with good tolerance125 and a larger-scale, controlled study of its influence on 
symptoms and conversion is currently underway126.  
  
Cognitive-behavioural and other non-pharmacotherapetic interventions   
 CBT and psychosocial therapy were reported, alone and in association with antipsychotics, to 
moderate negative, emotional and social symptoms in CHR subjects as well as reducing the risk of 
later transition102-109 (Table 1). Carer support promotes the efficacy of CBT, and family-based 
interventions suggested symptomatic benefits in a sub-set of CHR patients though, owing to small 
sample size and the specific trial design, no conclusions can be made concerning conversion127,128. 
Likewise, a pilot study of Cognitive Remediation Therapy suggested improved social function, but 
conversion was not reported129.  
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In a clinical setting, CBT and related therapies are more likely to be accepted by CHR subjects 
than antipsychotics, and certain National Guidelines advise CBT for (mainly symptomatic 
treatment of) CHR patients31,34,35. Nonetheless, high patient commitment and practitioner training is 
required for success110,130. Thus, further, well-powered studies are required to confirm the efficacy 
of non-pharmacotherapeutic interventions for diminishing transition112,113. Encouragingly, a 
recent report underpinned the overall cost-effectiveness of CBT for reducing conversion130. 
 
Experimental studies of course-alteration in rodent models for 
schizophrenia  
Studies of adolescent interventions in rodent models for schizophrenia   
Paralleling clinical work, many studies have exploited developmental and genetic models for 
schizophrenia131 to determine whether adolescent/early adulthood treatment can prevent a 
schizophrenia-like phenotype in adult rodents (Table 2). 
 
Omega-3 and other clinically-tested agents with anti-inflammatory/anti-oxidant properties 
Administered as a dietary supplement to adolescent rats, Omega-3 blunted the behavioural, 
cognitive and biochemical disruption provoked by long-term exposure of young adult rats to 
ketamine132,133. These observations are intriguing, but the data would benefit from extension to 
more conventional models for schizophrenia. The underlying mechanisms of action also merit 
further investigation. Nonetheless, Omega-3 possesses anti-inflammatory and anti-oxidant 
properties134-136 and similar effects may intervene in the experimental actions of several other 
clinically-tested - in established schizophrenia - agents. 
Adolescent treatment of rats gestationally exposed to the viral mimic 
Polyriboinosinic:Polyribocytidylic (“Poly I:C”) with the anti-inflammatory Cyclo-Oxygenase-2 
inhibitor, Celecoxib, blocked the adult appearance of supersensitivity to the NMDA antagonist, 
dizocilpine137. Celecoxib has shown preliminary evidence of utility as augmentation therapy in 
schizophrenia, but this awaits confirmation134,135. Minocycline interacts with microglia and 
oligodendrocytes to exert a palette of anti-inflammatory, anti-oxidant and neuroprotective actions on 
white and grey matter134-136: it also promotes NMDA-receptor mediated transmission138. It blocked 
behavioural deficits and microglial activation in adult rats which had received an intra-hippocampal 
injection of the pro-inflammatory agent, lipopolysaccharide, just after birth139. This is interesting since 
minocycline, while not without risks, is well-tolerated, and has been evaluated as an adjunct in 
established schizophrenia. Currently, its efficacy awaits corroboration, though it appears to be 
most active in early schizophrenia and against negative symptoms8,134-136,140. Encouragingly, 12 
months add-on minocycline in recent-onset schizophrenia reduced symptoms and protected from grey 
matter loss in fronto-temporal cortex141.  N-acetyl-Cysteine, another drug possessing anti-
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inflammatory properties, promotes the activity of the anti-oxidant glutathione (deficient in early 
schizophrenia), enhances mitochondrial integrity, acts at the cysteine-glutamate transporter and (like 
minocycline) facilitates NMDA signalling135,136,142. In small-scale trials of schizophrenia, adjunctive 
N-Acetyl-Cysteine improved negative symptoms, social functioning and deficits in mismatch 
negativity, facets characteristic of the prodrome142,143. Again, confirmation of efficacy is outstanding. 
Nonetheless, using a neonatal Ventrohippocampal lesion (VHL) model, adolescent administration of 
N-Acetyl-Cysteine to rats blocked deficits in Pre-Pulse Inhibition in adults: this action was reproduced 
by the anti-inflammatory/anti-oxidant agent, ebeselen, underscoring the relevance of these components 
of the activity of N-Acetyl-Cysteine144.  
 
Antipsychotics and their potential mechanisms of action 
Upon administration during adolescence, antipsychotics consistently blunt the adult 
hyperlocomotor response to amphetamine and the disruption of sensorimotor gating. Globally similar 
findings have been made in mice and rats using VHL and pro-inflammatory developmental models for 
schizophrenia145-151. What is less clear is how the effects of antipsychotics are expressed. A role for D2 
receptor blockade is supported by clinical data suggesting that subcortical dopaminergic over-activity 
commences during adolescence (see above). Indeed, D2 receptor stimulation in adolescent mice 
disrupts dendritic spine morphogenesis and has a long-term deleterious impact on cortico-hippocampal 
connectivity152.  Furthermore, the Sandy mouse strain (which lacks the putative schizophrenia risk 
gene, dysbindin) has abnormally high cell-surface levels of D2 receptors: sustained treatment of 
adolescent animals with eticlopride prevented both disruption of entorhinal cortex-hippocampal 
connectivity and impaired working memory in adults152. Nevertheless, the potent prevention by 
risperidone of amphetamine-supersensitivity in a VHL model in rats suggests a role for its         
5-HT2A antagonist properties, likewise implicated in blockade of the actions of PCP in 
rats145,146,149,151,153. In addition, 5-HT1A agonism may be involved in the effects of aripiprazole (and 
clozapine), ostensibly via neuroprotective/neurorestorative actions148,151,154.  
Additional studies using a broader range of (translatable) measures are needed to clarify 
the clinical relevance of these experimental findings.  
 
Antidepressants, anxiolytics and modulators of neurotransmission  
CHR subjects are frequently treated with antidepressants for relief of anxiety or depression, 
and data from clinical audits are consistent with (though not proof of) a decreased likelihood of 
developing psychosis32,34,35. Hence, it is of note that sustained treatment of Poly I:C mice during 
adolescence and young adulthood with fluoxetine decreased both amphetamine-hyperlocomotion and 
disruption of sensorimotor gating: both indirect recruitment of 5-HT1A receptors and modulation of 
neurosteroids may be involved148,150. However, caution is warranted since fluoxetine disrupted 
gating in control subjects and failed to prevent the increased sensitivity to dizocilpine. Another 
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developmental model for schizophrenia, prenatal exposure to the mitotoxin and disruptor of 
neurogenesis, “MAM”, is associated with anxiety155. The ability of peri-pubertal diazepam to prevent 
dopaminergic hyperactivity in adult animals was attributed to its stress-alleviating properties156. 
Further studies of antidepressant and anxiolytic agents appear justified in light of their extensive use in 
CHR subjects. 
Metabotropic glutamate receptor (mGluR)-5 and -nicotinic receptor positive allosteric 
modulators (PAMs) possess pro-cognitive properties attracting interest for symptomatic treatment of 
established schizophrenia12. Accordingly, mGluR5 PAMs, applied acutely, rescued impaired social 
cognition in adult rats neonatally exposed to phencyclidine.  Of greater significance, however, chronic 
administration during adolescence enduringly blocked the appearance of cognitive deficits throughout 
adulthood157. Since adult administration was not effective, prevention was clearly the underlying 
mechanism. Several mechanisms are implicated: anti-inflammatory properties at microglia, 
recruitment of oligodendrocytes to reduce white matter fibre loss, induction of BDNF, neuroprotective 
and anti-apoptotic properties157. These data are underpinned by another study where adolescent 
treatment with a mGluR5 PAM impeded the adult development of deficits in sensorimotor gating158. 
This action was mimicked by a -nicotinic agonist that was proposed to act by a different 
mechanisms, possibly involving receptor desensitization158. 
 
Modulation of intracellular protein networks and histone acetylation 
The scaffolding hub protein, Disrupted in Schizophrenia (DISC)1, is a genetic risk factor for 
psychosis and several other psychiatric disorders, with DISC1 mutant mice displaying developmental 
anomalies related to schizophrenia131,159. DISC1 is enriched post-synaptically at NMDA receptors 
where it interacts with protein partners like Kalirin-7 to control synaptic plasticity and 
dendritogenesis160.  While direct manipulation of DISC1 may not be feasible, targeting Kalarin-7 - 
down-regulated in schizophrenia - might counteract deficient synaptic plasticity159,160. Other DISC1 
protein partners include “Rac1” (a Rho family GTPase). Rac1 modulates p21 Kinase, and p21 Kinase 
inhibition during adolescence prevented any further loss of dendritic spines in mice subjected to 
DISC1 knockdown at embryogenesis, possibly by blocking excess synaptic pruning (see below)161.  
These data resemble findings from mouse models of Fragile X where p21 Kinase inhibition similarly 
rescued dendritic deficits162 and suggest a way of preventing the structural anomalies underlying 
schizophrenia. Moreover, they indicate how, via manipulation of interacting proteins, it may be 
possible to make the transition from anomalous molecular circuits in animal models to tractable 
targets for development of course-altering medication in CHR people. 
A rather different approach to course-alteration is represented by cerebrolysin, a 
neurotrophic cocktail under investigation for the treatment of stroke and vascular dementia163. 
When given during adolescence, cerebrolysin decreased the onset of structural, neurochemical and 
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behavioural deficits in adult mice subjected to VHL during the post-natal period164. The (probably 
multiple) mechanisms of action of cerebrolysin await further elucidation and it is unlikely to be 
pursued as a clinical option, but these data are of interest in supporting the potential utility of 
neuroprotective interventions. 
The ion channel and GABAergic modulator, valproate, is a candidate for potential 
clinical trials since, despite risks in pregnant females, it is well-tolerated and used in young 
people as a mood stabilisor26,33. Valproate prevented the emergence of hyperlocomotor activity and 
sensorimotor gating deficits in a mutant DISC1 mouse line when given to young adults, an action 
related to inhibition of excessive glial proliferation in hippocampus165. Further, Valproate blocked 
the disruption of sensorimotor gating and induction of Histone Deacetylase (HDAC)2 in the 
above-mentioned “mitotoxin” model for schizophrenia166. Valproate is a pan-inhibitor of HDACs26. 
Though a role for HDAC inhibition in its actions remains to be formally demonstrated, adolescent 
administration of the more selective HDAC inhibitor, sodium butyrate26 prior to chronic phencyclidine 
impeded the development of behavioural-cognitive deficits167. Sodium butyrate likewise prevented the 
appearance of cognitive impairment and dopaminergic hypersensitivity when given to adolescent rats 
that had sustained neonatal inflammatory damage to the hippocampus168.  
 
Behavioural and environmental interventions 
Non-pharmacotherapeutic interventions can also be explored in rodent models. Intriguingly, 
the preventive effects of sodium butyrate were reproduced by environmental enrichment, consistent 
with a role for epigenetic mechanisms167. While the therapeutic relevance of environmental 
enrichment is unclear, this is mechanistically interesting and globally supports the notion that 
non-pharmacotherapeutic interventions can change outcome when applied early. Furthermore, 
mimicking CBT in CHR subjects, cognitive training of neonatal VHL rats during adolescence 
ameliorated both: 1), inter-hippocampal synchrony of field oscillations and 2), cognitive control 
(ability to prioritise relevant over irrelevant information) in a test of reversal learning that recruits the 
PFC169. The apparently course-altering effects of early cognitive intervention are, then, sustained well 
into adulthood.  
 
Collective pre-clinical evidence for effectiveness of pre-symptomatic interventions 
In conclusion, there is a surprisingly diverse, convergent and robust body of data showing that 
early intervention in rodent models for schizophrenia can modify the appearance of “symptoms” in 
adults. Underlying mechanisms are unlikely to be unitary and only a limited number of agents have 
been examined. Nonetheless, these observations provide a promising platform for a broader 
experimental evaluation of novel strategies for altering the course to (and of) schizophrenia.  
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Novel, potential mechanisms of course-alteration: from pathophysiology to 
pharmacotherapy  
Network-based concepts: multiple hierarchies of intervention  
Network thinking and, more specifically, Graph Theory, provide a useful framework for studying 
the disruption of cerebral circuits in schizophrenia and for devising approaches for course-
alteration36,84,170. Indeed, schizophrenia is a disorder of disconnectivity that reflects progressive 
disruption of intra-neuronal and cerebral circuits rather than the loss or overactivity of any single 
cellular signal, neurotransmitter or brain region. Once disrupted, networks may phase-shift to an 
alternative steady state which is hard to reverse, underpinning the need to treat as early as 
possible30,84,170.  From a network perspective, interneurons like fast-firing GABAergic basket (and 
chandelier) cells in the PFC can be considered the nodes (“hubs”, if crucial) with longer, inter-
connecting projection neurons such as glutamatergic pyramidal cells the edges (vectors)14,36,170-173. For 
an individual neuron, the soma might be considered the node and its axon (and dendrites) the edges.  
Disruption of either hubs or edges can provoke network failure, and both are legitimate targets for 
therapy. Though medication interacts with specific protein(s) rather than networks per se, 
pharmacotherapy can target specific hubs at many hierarchical levels to improve the operation of 
dysfunctional networks and hence reduce the risk of schizophrenia (Figure 4). Drug associations, 
multi-target agents and non-pharmacotherapeutic interventions like brain stimulation and psychosocial 
training may be particularly appropriate for protecting and restoring degraded neural networks36,170 
(Figure 4).  
 
Deregulated cortico-limbic GABA-glutamatergic circuits: the need for resynchronisation 
A highly consistent change in patients and animal models for schizophrenia is a down-
regulation of fast-spiking  frontocortical GABAergic interneurons which reciprocally interact with 
glutamatergic pathways14,29,172,173. The developmental perturbation of GABAergic interneurons is 
related to several factors including: NMDA receptor hypoactivity; abnormal regulation by astrocytes 
and neurotrophins (BDNF); disruption of the extracellular matrix; insufficient energy supply and cell-
autonomous anomalies14,29,172-174. Deregulation of GABAergic interneurons leads to an imbalance of 
excitatory/inhibitory transmission, desynchronisation of cortical and cortico-subcortical circuits,  
disruption of neural oscillations and gamma-band synchrony, and impaired cognition and 
mood12,14,25,29,84,171-173. Further, perturbation of GABA-glutamatergic coupling in the PFC in turn 
disrupts subcortical circuits and dopaminergic transmission and is linked to the emergence of 
psychosis29,84,88,153,171,172 (Figure 4). In young CHR subjects, a reduced dynamic range of frontocortical  
GABA-glutamatergic networks may aggravate cognitive inflexibility, exaggerate sensitivity to stress 
and increase vulnerability to recreational drugs like cannabis which reciprocally interferes with 
GABAergic transmission84,171-173,175. 
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In view of these observations, the protection of GABAergic-glutamatergic circuits from 
disturbance, and their restoration following disruption, provides an instructive and integrative 
framework for the following discussion of potential course-altering mechanisms for schizophrenia.  
 
Restoring normal patterns of GABAergic transmission 
Direct modulation of GABAergic signalling: Activation of GABA-A2 receptors on pyramidal cells 
has been evaluated as an adjunct in chronically-ill subjects for improving cognition, but results were 
disappointing12,14,172. As pointed out below, evaluation earlier in the disorder for network-
resynchronisation and course-alteration might prove more successful. Another possible strategy would 
be pregnenolone. This neurosteroid acts as a PAM at NMDA receptors and is metabolised into 
allopregnenolone, a PAM at GABA-A receptors. Supporting such a study, there are encouraging 
findings with adjunctive pregnanolone, negative symptoms and functional outcome in newly-
diagnosed patients8,176,177.  
Recent work has unveiled some other, less familiar ways in which aberrant GABAergic 
transmission might be normalized to interrupt the path to psychosis. 
The Na-K-Cl co-transporter (NKCC1), which is genetically linked to schizophrenia is 
involved in expressing the postsynaptic effects of GABA-A receptors, as well as neural circuit 
formation during brain maturation178,179. A developmental decrease in the ratio of NKCC1 to the K-Cl 
co-transporter explains the gradual transition from depolarising to hyperpolarising actions of 
GABA178. Conversely, an aberrantly high level of NKCC1 vs K-Cl co-transporters - together with 
anomalous NKCC1 splicing - is related to network anomalies of developmental disorders178.  These 
findings suggest that early inhibition of NKCC1 may restore the balance of excitation/inhibition, 
promote network synchrony and interrupt the path to psychosis. Underpinning interest in modulation 
of NKCC1, the antagonist bumetanide improved facial processing in autistic children (3-11 years 
old)180. Further in an experimental model of autism, prenatal treatment of mothers with bumetanide 
precluded emergence of behavioural deficits in offspring181. While bumetanide poorly crosses the 
blood-brain barrier, more brain-penetrant and selective ligands might be an option for preventative 
treatment of CHR patients178.  One caveat is that most rodent studies of NKCC1 have been 
undertaken in early post-natal life. Nevertheless, bumetanide enhanced social cognition in 
adolescent and young adult autists, supporting the relevance of NKCC1 to events occurring 
around the time of conversion to schizophrenia182. Further, polymorphisms in NKCC1 affect 
PFC function and cognition in adult schizophrenics179. 
Like their GABA-A receptor counterparts, pre and post-synaptic GABA-B receptors are 
involved in the establishment, operation and integration of cortical networks. Their actions are 
partially mediated via BDNF and embrace the control of neural migration, synaptogenesis and neurite 
growth183. Suggesting a link to schizophrenia, activation of GABA-B receptors counters the imbalance 
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in excitation/inhibition, gamma-asynchrony and deficits in sensorimotor gating, cognition and 
behaviour seen in: 1), mice with genetic NMDA receptor hypofunction184 and 2), rodents exposed to 
psychostimulants: these actions are expressed at least partly in the PFC185. In addition, the GABA-B 
agonist, arbaclofen, improved social behaviour in children with Fragile X186. Small-scale clinical trials 
of baclofen in established schizophrenia were unsuccessful, but GABA-B receptor stimulation would 
justify evaluation in the CHR phase for reduction of transition.  
 
Intervening at ion channels on GABAergic interneurons: Another potential target would be Kv3 
potassium channels which rapidly repolarise GABAergic interneurones following excitation: this 
action permits precise patterns of high-frequency firing, coordination of cortical networks, and 
synchronisation of gamma-oscillations in relation to goal-related behaviour and cognition29,84,171,172. 
Kv3.1b and Kv3.2 expression peaks during early development but persists through adolescence 
into adulthood, and levels of the former were decreased in the PFC of chronic schizophrenics187. This 
decrease was countered by antipsychotics187. Information on Kv3 channel levels in brain are 
lacking from CHR subjects, but direct Kv3 ligands are an intriguing prospect for symptom relief and 
prevention of transition in CHR subjects. Indeed, Kv3 channel inducers alleviated cognitive and 
negative symptoms in a rodent, sub-chronic phencyclidine model of schizophrenia in which Kv3 
channel expression was reduced188,189. Whether Kv3 channel inducers, applied during adolescence, 
impede the appearance of symptoms in animal models for schizophrenia, would be important to 
determine.   
 
The challenge of intracellular targets: Neuregulin-ErbB4 and downstream proteins: Neuregulin-
1/ErbB4 receptor signalling plays an important role in the differentiation and migration of cortical 
GABAergic interneurons, and in other developmental processes like axon myelination29,159,190 (Figure 
4A). Neuregulin-1 is strongly linked to schizophrenia based on: genetic association; changes in its 
levels in the brain (and lymphocytes) of patients; and the “schizophrenia-like” phenotype of its 
manipulation in rodents, including deletion solely in PFC populations of GABAergic interneurons 
where it is enriched29,53,159,190. Furthermore, Neuregulin-1 over-expression in pyramidal neurones 
triggers synaptic and behavioural anomalies relieved by extinction of its expression, suggesting that 
effects of aberrant ErbB4 signalling and a schizophrenic phenotype might be reversible after 
emergence191. Finally, Neuregulin-1/ErbB4 recruit the DISC-1 partner, Kalarin-7, to influence the 
plasticity and morphology of dendrites in interneurons159,160,190.  
Despite all this, Neuregulin-1 illustrates the challenges of trying to therapeutically 
manipulate a cellular hub protein159.  Early intervention to prevent abnormal neuronal migration is 
not yet feasible.  Increases and decreases in Neuregulin-1/ErbB4 signalling have been reported in 
schizophrenia, and both are deleterious in animal models so medication would need to be tightly 
regulated around a set-point190. In addition, Neuregulin-1 has multifarious (and partly sex-specific) 
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actions across many cells types159. Finally, administration of Neuregulin-1 to rodents is not 
consistently favourable: for example, early-life exposure results in persistent over-stimulation of 
mesolimbic DA transmission190,192. Thus, while focussed manipulation of Neuregulin-1/ErbB4 
signalling in GABAergic interneurons might be favourable, this would be hard to specifically realise 
as a strategy for course-alteration. 
 One potential solution may be to act at proteins downstream of Neuregulin-1, and an ErbB4 
“CYT-1” isoform over-expressed in schizophrenia recruits the Phosphoinositide-3/Atypical Kinase 
signalling cascade190,193. One of two constituent proteins (“PIPK3CD”) encodes a p100-subunit. 
Pharmacological inhibition of p100 countered anomalies in a VHL model of schizophrenia, so study 
of inhibitors prior to emergence of symptoms would be warranted193. Finally, it might be possible to 
act at inhibitory GABAergic synapses via modulation of the risk gene, Neurexin-1 in interaction 
with its post-synaptic partner, Neuroligin-155,53,92.  
 Thus, there may be openings for manipulating GABAergic, glutamatergic and other 
modes of transmission via actions at intracellular networks disrupted in schizophrenia, but this 
currently remains challenging.  
 
Epigenetic strategies for normalising faulty neurodevelopment leading to schizophrenia 
Countering anomalous epigenetic control of GABAergic interneurons.  Anomalous control of 
gene transcription by DNA methylation and histone post-translational marking, together with aberrant 
regulation of mRNA translation by miRNAs, lies at the interface of genetic and environmental triggers 
for schizophrenia25,26,194-195. Disrupted epigenetic mechanisms may be inherited, provoked by de novo 
CNVs and mutations, and/or triggered by diverse environmental events ranging from perinatal 
infection to adolescent drug abuse, which increase the risk for schizophrenia25,26,66,191,195,196.  
Interestingly, the best-documented link between aberrant epigenetic mechanisms and the onset 
of schizophrenia has been found with GABergic neurones. Thus,  DNA promoter hyper-
methylation and aberrant patterns of histone acetylation/methylation in PFC (and hippocampal) 
populations of GABAergic interneuron  lead to reduced synthesis of GABA and Reelin, together with 
concomitant down-regulation of mGluR2 receptors and BDNF 25,26,196-198.  
 As regards strategies for reviving GABAergic interneurones, reducing promoter 
hypermethylation may be feasible by: interfering with DNA-Methyltransferases, inducing endogenous 
Demethylases like “Gadd45-”, or using  engineered constructs to mimic their activity and enhance 
demethylation. However, in all cases, safe and brain-penetrant agents will be required for clinical use 
25,26,198,199.  More accessibly, GABA promotor demethylation can be elicited upstream using agonists at 
mGluR2Rs which rekindle GABA, reelin and BDNF expression via induction of the dimethylase, 
Gadd45-25,26. Furthermore, nicotinic 24 agonists harness GABA synthesis by reducing the 
20 
 
NRDD CA RESUBMITTED TEXT GLOSS REFS LEGENDS 21 10 2015 s 
expression of DNA-Methyltransferases and disrupting repressive activity of the DNA-binding protein, 
“MeCP2”25.   
Approaches other than demethylation might also be used to resuscitate genes repressed in 
GABAergic interneurons. By interfering with histone deactylation (aberrant in schizophrenia), 
Valproate (vide supra) re-activates GABA synthesis both directly and via recruitment mGluR2 
receptors 25,26,200.  While modulators of acetylation affect numerous genes, agents modifying histone 
methylation (likewise disrupted in schizophrenia) act at a more restricted set: they are well-advanced 
in oncology and could be experimentally tested for GABA interneuron revival and course-alteration in 
schizophrenia26,201.  
Another possibility to promote GABAergic transmission may be via miRNAs which fulfill 
diverse regulatory roles in neurodevelopment and interact with DNA and histone methylation. They 
are highly dynamic during puberty, impacted by risk factors from CNVs to peri-natal inflammation to 
adolescent stress, and deregulated in schizophrenia26 194,202,203. Interestingly, GABAergic interneurons 
possess a distinctive complement of miRNAs204 and their activity is under the control of several 
miRNAs including miR-137 (genetically linked to schizophrenia), miR-132 (a controller of synaptic 
plasticity) and miR34a (modulated by NMDA receptors) (Suppl Box 2)26,194,203. 
 
Broader relevance of epigenetic strategies to course-alteration Epigenetic anomalies in 
schizophrenia are not restricted to GABAergic interneurons. For example, a broad suite of 
changes in miRNA affects many mediators like  glutamate, D2-receptors, Kalarin/p-21 Kinase 
and ErbB425,26,194,203,205 (Suppl. Box 2). Epigenetic medication for course-alteration would be 
especially attractive since it acts at the network level to modulate entire clusters of proteins. 
Further, such agents could have beneficial symptomatic effects in the CHR state on cognition 
and mood26. The major focus is currently on better understanding the functional roles of 
epigenetic mechanisms, and exploiting them as biomarkers. For therapeutic exploitation, it will 
be necessary to: 1) establish which epigenetic factors drive (vs oppose or merely accompany) 
pathophysiological processes leading to schizophrenia and 3) determine the optimal mode, 
timing and duration of therapy.   
 
Promoting the connectivity of neural circuits 
Protecting the operation and integrity of cerebral networks. Though less well-documented than 
GABAergic mechanisms, there are several other potential approaches for enhancing cerebral 
connectivity and hence reducing the risk of transition. One of these focusses on cytoskeletal 
microtubules since their disruption in schizophrenia perturbs the structural support of 
neurones, impedes axonal transport and compromises synaptic plasticity (Suppl. Box 3). Two 
further strategies are outlined below, both particularly relevant during the therapeutic window 
of adolescence and young adulthood. 
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Targeting oligodendrocytes to counter aberrant patterns of myelination: In comparison to 
extensive subcortical myelination during childhood, intra-cortical and cortico-subcortical myelination 
intensifies during adolescence and young adulthood: that is, at the time of transition to psychosis206,207.   
Myelin requires continuous renewal in the face of damage by trauma, nutritional deficits, hypoxia, 
stress and inflammation206,208,209. These are all risk factors for schizophrenia and the white matter 
disruption seen prior to and following diagnosis of psychosis reflects both their impact and faulty 
oligodendrocyte-controlled programs of myelination206,208,209. Cortical white matter (myelin) deficits 
and oligodendrocyte abnormalities have been related to the onset of network asynchrony, negative 
symptoms, hallucinations, impaired sensory processing, cognitive decline and perturbed dopaminergic 
and glutamatergic transmission204,206,208,210,211.  
Clearly, then, myelin and oligodendrocytes are potential targets for course-alerting therapy. It 
has been speculated that antipsychotics (possibly via inhibition of Glycogen Synthase Kinase-3beta) 
exert transient neuroprotective properties for white matter212. Further, the anti-inflammatory and anti-
oxidant actions of pregnenolone, minocycline and Omega-3 (see above) have a trophic, 
neuroprotective  influence on myelin100,134-136,175,176 which might also benefit from neutralisation of 
retroviruses (see below). Several other concepts are emerging for opposing the developmental 
deregulation of oligodendrocytes and myelination that accelerates the course to schizophrenia206,213,214. 
For example, Valproate and Lithium promote myelination and oligodendrocyte function214,215  while 
the anti-parkinson agent, benztropine, exerts myelin-repairing activity by a mechanism involving 
M1/M3 muscarinic receptor antagonism18. In addition, pro-myelination and neuroprotective “GRE30” 
estrogen receptors are enriched in oligodendrocytes216.  
 
Countering excessive synaptic pruning during adolescence: Corticolimbic synaptic density peaks 
in infancy around 2-4 years followed by the pruning of excess synapses, a process occuring most 
intensely during adolescence and continuing until the third decade. Surviving synapses are stabilized 
so network connectivity is globally improved217,218.  There is evidence that synaptic pruning in the 
dorsolateral PFC and hippocampus is disproportionate in schizophrenia, which would aggravate 
the abnormal coupling of glutamatergic-GABAergic neurones and compromise the operation of 
neural circuits71,171,217-219. For example, in interaction with Kalirin-Rac, the “Actin-related 
protein” 2/3 complex promotes actin polymerization and spine formation: it’s disruption 
mirrors excess pruning, with a loss of synaptic contact on pyramidal cells leading to over-
activity and, via a long-range projection to the ventrotegmental area, activation of mesolimbic 
dopaminergic pathways and psychosis71.  Further, together with reduced neuronal size, over-pruning 
may help account for the reduction in cortico-hippocampal spine density/grey matter that anticipates 
and characterizes schizophrenia71,76,77,217,219.  
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Several, therapeutically-accessible mechanisms disrupted in schizophrenia might be able 
to modify the disruption of synaptic pruning and spine dynamics thought to anticipate psychosis, 
including the DISC1-Kalarin-Rac axis, Neuregulin-ErbB4, estrogen signaling, BDNF and 
NMDA receptors (see above)159,161,220-223. Other opportunities might emerge from the role of 
cytokines in anomalous astrocytic and microglial sculpting of synapses,218,222  and, based on 
studies of defective synaptic pruning in autism, from “mammalian target of rapamycin”-
regulated autophagy, which also controls pruning223.  
The latter observation underpins the relevance of pruning to developmental disorders in 
general, and indicates that an optimal “degree” of  (neither too much nor too little) is needed for 
normal development. However, as discussed elsewhere217, any causal link between aberrant 
pruning and psychosis remains to be further confirmed, and evidence that normalization of 
pruning impedes appearance of psychosis in animal models for schizophrenia is awaited. 
 
Countering neuro-inflammation, immune deregulation and the impact of infections 
Anti-inflammatory treatments to counter short and long term repercussions of infection: Genetic 
studies have found an association of schizophrenia with the Major Histocompatibility Complex224 and 
schizophrenia and CHR subjects display robust evidence for inflammatory and neuroimmune 
disruption (see above)134,135,225. Further, bacterial or viral infection of the mother during pregnancy 
elicits a immune-inflammatory response (“Maternal Immune Activation”) which deleteriously impacts 
cerebral development of the foetus, while post-natal infection likewise compromises normal 
maturation of the brain27,28,225. Inflammation is linked to microglial release of pro-inflammatory 
cytokines like Interleukin-1/Interleukin-6, Tissue Necrosis Factor- and kynurenate (a NMDA/7-
nicotinic receptor antagonist). Collectively, they exert deleterious effects on neurones, astrocytes and 
oligodendrocytes leading to anomalous neural proliferation/differentiation, synaptic plasticity and 
myelin formation and, later in life, disruption of GABA-glutamatergic networks28,34,135,137,226. 
Importantly, then, perinatal inflammatory events provoke long-lasting changes in immune status (such 
as an up-regulation of Interleukin-6 expression) that persist into young adulthood both in human 
patients and in animal models for schizophrenia. These enduring changes render subjects more 
sensitive to second-wave risk factors like stress, which likewise perturb immune function and unveil 
latent structuro-functional deficits28,227-229. Of particular interest, early-life immune disruption 
leads to abnormal PFC levels of inflammatory mediators and anomalous GABAergic 
transmission in adult mice230.  
Treatment could not realistically be instigated at the time of immune disruption/infection if 
during pregnancy or infancy. Conversely, owing to above-mentioned longer-term repercussions of 
perinatal infection - and to pro-inflammatory events in adolescence/young adulthood - interventions 
could be undertaken in CHR subjects. In fact, anti-inflammatory properties may well be implicated in 
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the clinical influence of Omega-3 upon conversion, and in the preventive actions of Omega-3, 
minocycline, N-acetyl-Cysteine and Celecoxib in animal models for schizophrenia (Tables 1 and 
2)100,134,135. The latter agents and Aspirin, likewise evaluated for efficacy as an adjunct in 
schizophrenia135  merit then consideration for trials of course-alteration. Another candidate would be 
the neurosteroid and GABA modulator, pregnenolone which displays complementary anti-
inflammatory properties176,177. 
These and other agents directly targetting anti-inflammatory mechanisms, like cytokine 
modulators, warrant experimental exploration in models of course-alteration. 
 
Neutralising a Retrovirus trigger of neuro-inflammation: One consequence of infection with 
bacteria and viruses (such as Herpes Virus-2) and parasites (like Toxoplasma gondii) is the revival of 
dormant Human Endogeneous Retroviruses (“HERV”)231,232. Neutralisation of their pro-
inflammatory protein envelopes by passive immunisation is under investigation for the treatment of 
multiple sclerosis, and a comparable course-altering strategy might be applicable to course-alteration 
for schizophrenia232 (Suppl Box 4). 
 
Restoring the equilibrium of the intestinal microbiome:  The intestinal microbiome is important for 
mental (and physical) health and disruption is related to anomalous neurodevelopmental processes 
leading to disorders like autism and schizophrenia28,233. Opportunities for course-altering intervention 
are suggested by an interrelated suite of developmental anomalies triggered by early-life intestinal 
infection-inflammation: an abnormal gut microflora; structural damage to the gut; and increased 
intestinal permeability and excessive penetration of bacteria and their metabolites/toxins into the 
circulation234,235. Potentially benign ways of reducing the risk of psychosis include: pro-biotic, non-
pathogenic bacteria like bifidobacteria which affect central GABAergic transmission, and agents that 
prevent bacterial translocation to the circulation201,234-236. As regards antimicrobial agents, it might be 
asked whether Minocycline exerts its putative actions in schizophrenia at least partially via an impact 
on the gut microbiome. Nonetheless, it is unclear just how specific “microbiotic” interventions 
would be for reducing the risk of schizophrenia compared to a broader influence on mental and 
physical health234. Further, rigorous experimental and clinical studies are required to: 1), 
confirm any causal relationship between an abnormal gut microbiome and pathophysiological 
changes that ultimately result in schizophrenia and 2), identify potential therapies for their 
control.  
 
Protecting young CHR subjects from life-style and environmental risk factors 
The transition to schizophrenia occurs at a time when the adolescent/young adult brain is 
undergoing a major structural and functional reorganisation. More generally, it is: enduring the 
onslaught of gender-specific hormones, facing increased energy demands, experiencing shifts in 
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processes of decision-making, behavioural control and reward mechanisms, and confronting an 
increasingly complex social, cultural, cognitive and emotional environment63,237,238. Accordingly, the 
brain is especially vulnerable to disruption. However, rather than some inevitable (or stochastic) 
progression to schizophrenia, conversion is likely triggered by a new wave of risk factors including a 
triad of mutually-aggravating hits: 1), poor resistance to psychological stress, 2), social isolation and 
3), excessive consumption of drugs of abuse, especially cannabis (Suppl Figure 2). While primary 
prevention (avoidance) and education are desirable, there is considerable interest in psycho-
social/cognitive-behavioural and pharmacotherapeutic interventions to counteract these risk factors 
and decrease conversion (Box 3).  
 
Perspectives for accelerating progress towards course-altering therapy  
Novel cellular models for probing pathophysiology and  identifying new targets  
A major challenge faced in developing course-altering medication is limited understanding of cellular 
anomalies involved in transition.  One way of addressing this knowledge-gap would be induced 
pluripotent stem cells (iPSC)  for: 1), characterisation of perturbed developmental processes 
underlying schizophrenia; 2), analysis of its genetic, cellular and molecular substrates and 3), 
identification of novel mechanisms for prevention and rescue239,240. IPSCs from patients and CHR 
subjects could be differentiated into networks of GABAergic, glutamatergic and/or dopaminergic 
neurones permitting exploration of both intra and intercellular communication and the identification of 
potential course-altering strategies241. Compared to monogenic diseases, iPSC models for 
schizophrenia present a major challenge yet, as outlined in Box 4, considerable progress is now being 
made. 
 
Optimising the use of animal models for schizophrenia  
Despite the availability of many well-characterised animal paradigms for studying 
schizophrenia, all have limitations and none has, as yet, been specifically designed to study 
course-alteration131. Hence, the important issue of which animal models, procedures and 
readouts are best-adapted to this goal is considered in Box 4.  
 
Improved linking of experimental with clinical studies of course-altering therapies 
To enhance the predictive validity of animal models, it would be instructive to integrate 
“translational” measures expoitable in clinical investigations. To this end, procedures currently in use 
for characterising CHR subjects and monitoring the efficacy of treatment should be more 
systematically applied to studies of prevention in rodents. Endocrine, immune and biochemical 
readouts from the circulation are easily accessible, while quantification of GABAergic, 
glutamatergic and DA transmission, as well as MMN interrogation of sensory processing, are 
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likewise readily performable. Recent technical advances now make it feasible to analyse in small 
animals structuro-functional changes that trigger and signal the onset of psychosis using grey 
matter MRI, fMRI studies of cerebral connectivity and EEG analyses of neural networks242-244. 
Mirroring work in animals131,153, one promising translational approach in humans is the use of 
ketamine at sub-psychotic doses in volunteers to mimic the perturbation of glutamatergic and 
GABAergic transmission seen prior to the FEP245. FMRI and cognitive testing can be undertaken in 
parallel, and this procedure would be useful for early clinical exploration of novel strategies for 
course-alteration.  
 
Biomarkers for tracking and predicting clinical efficacy of course-altering medication 
It is desirable to: 1), link a risk factor to a pathophysiological mechanism favouring onset or 
progression of schizophrenia: 2), identify a strategy for rectification and 3) develop biomarkers both 
for identifying subjects to treat and for predicting therapeutic efficacy of the intervention in 
question33,52. Such biomarkers should serve to track and predict medication efficacy from the 
inception of treatment since a clinical reduction in course-alteration might only become clear 
years later. That is, the goal is to find a surrogate biomarker that: 1), directly reflects the 
pathophysiological mechanism targeted and 2), changes in which are linked with and predictive 
of an eventual reduction of transition. Many procedures would be similar to those used to detect and 
stratify CHR subjects (see above, Figure 3B), but details and application would differ. Further, during 
medication, biomarkers should be coupled to measures of drug exposure and target engagement.  
The NAPLS study of CHR subjects exemplifies the multi-pronged approach that can be used48 and 
surrogate readouts of efficacy include, depending on medication of action: cortisol levels for drugs 
countering HPA axis overdrive, circulating levels of cytokines for anti-inflammatory agents, changes 
in lymphocyte patterns of histone marking for epigenetic modulators26,190, and GABA/Glutamate 
levels in PFC for therapies designed to re-coordinate GABA-glutamatergic networks10,59,61,63,69. More 
generalist strategies would be estimation of extracellular DA release/D2 receptor occupation in 
striatum, MMN measures of neural processing and structural MRI of the ventricles and 
hippocampus57,84,88,93. As a general rule, it would be important to employ multiple biomarkers 
both at the initiation of clinical trials and throughout their duration. 
Finally, in tracking the efficacy of course-altering medication, the influence of several 
variables not yet factored into clinical trials, like age of onset, potential “placebo” effects of 
treatment, gender and cultural differences also deserve consideration (Suppl. Box 5)246-248. 
 
A “hybrid” concept: symptom relief coupled to a reduction of transition  
Care of CHR subjects necessitates the relief of presenting symptoms - usually of greater concern 
to patients at consultation than an increased risk of conversion. In principle, a separate treatment might 
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be instituted to impede transition. However, control of symptoms in the CHR state may of itself and 
perhaps causally reduce the risk of progression to psychosis and other disorders (Figure 5). Such a 
“hybrid” strategy would have advantages compared to pure disease-modification: 1), alleviation of 
symptoms provides a functionally-relevant and patient/regulator-valued readout of target engagement 
and potential course-altering efficacy before longer-term measures of transition - hence derisking 
clinical trials of course-altering therapy16,32,34; 2), a common treatment for symptom-control and 
course-alteration would minimize poly-pharmacy; 3),  interventions may likewise delimit conversion 
to other disorders like bipolar depression23,34 and 4), medication would not be considered an 
“antipsychotic,” improving acceptability.  
In fact, as discussed above, Omega-3 and psycho-social/cognitive-behavoural interventions may 
both alleviate symptoms and reduce progression in CHR subjects, but it is unclear whether these 
actions are mechanistically linked. Concerning novel strategies, counteracting the adolescent risk 
factors, psychosocial stress, drug-seeking/cannabis abuse and impaired social cognition/social 
isolation is particularly attractive (Box 3) (Suppl Figure 3). Pharmacotherapeutic strategies include the 
pro-social modulator, Oxytocin249; CRF1 antagonists for relieving anxiety and moderating stress-
induced relapse of drug-seeking behaviour250; and dopamine D3 receptor antagonists for countering 
drug-abuse and promoting cognition251 (Box 3). 5-HT2A receptor blockade may also be of interest 
since it is well-tolerated, counters hallucinations and implicated in preventive actions of risperidone in 
rats153,252 (see above). As a final example, 5-HT2C receptor blockade is associated with anxiolytic and 
antidepressant properties and increased frontocortical dopaminergic transmission which may counter 
negative symptoms8,253.  
The most effective hybrid treatment may well be the judicious association of psycho-
social/cognitive-behavioural strategies with appropriate pharmacotherapy.  
 
Re-orienting agents evaluated in chronic schizophrenic for early course-alteration  
Certain classes of agent poorly active in chronic schizophrenia for symptom-relief might 
profitably be re-evaluated for course-alteration in the CHR state. This option was evoked above for 
anti-inflammatory agents, but there are several other intriguing possibilities. 
 GABA-A2 agonists disappointed in association with SGAs for amelioration of 
neurocognitive deficits in chronic patients but, administered to CHR subjects, they might delimit 
conversion (and improve symptoms) by resynchronising cortico-subcortical glutamatergic 
circuits14,29,171-173. Recruitment of hypoactive NMDA receptors upstream of GABAergic interneurons 
by agonists and inhibitors of glycine reuptake has yielded chequered results in schizophrenia, but the 
most compelling hints of efficacy were against negative symptoms which are present in the prodromal 
phase8,9,10. Hence, they might be re-positioned in CHR subjects. Supporting this idea, a pilot 24 week 
study254 reported beneficial effects of Glycine in CHR patients, but work on conversion remains to be 
undertaken. Intriguingly, D-Serine rather than Glycine gates dysfunctional NMDA receptors in the 
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PFC255 and D-Serine improved negative symptoms in a controlled study of CHR subjects, with larger-
scale studies (including measures of conversion) anticipated256. D-Amino-Acid Oxidase inhibitors for 
blocking D-Serine metabolism would be another therapeutic option257 or drugs blocking generation of 
the endogenous NDMA antagonist, kynurenate10,134. Levels of Kynurenate are elevated by 
inflammatory states that enhance the risk of schizophrenia134,135. Valproate is also of interest as an 
epigenetic regulator (see above), despite lack of evidence for efficacy in chronic schizophrenia26. 
There is, then, scope for re-orienting certain agents that were largely unsuccessful in chronic 
schizophrenia (usually as add-ons) to an earlier time-point in CHR subjects where they may interrupt 
progress of the disorder and be of symptomatic benefit - alone and/or in association with 
psychosocial/cognitive-behavioural therapies 
 
Evaluation of course-altering therapy after the first episode  
While the above discussion focussed on preventative interventions in CHR subjects, an 
alternative entry-point is just after the FEP. In reality, some “CHR” subjects will already have 
undergone a “pre-diagnostic” psychotic event (Figure 3) and treatment is urgent since duration of 
untreated psychosis correlates with unfavourable short and long-term outcome, a lower chance 
of remission, more severe symptoms and poor social integration34,35,83,258. In this sense, rapid 
intervention with antipsychotics might nominally be considered “course-altering”259. However, 
evidence for protective effects of SGAs against pathophysiological changes associated with psychosis 
is limited and of uncertain clinical relevance154,212,260-264. Moreover, in certain patients, decreases in 
brain volume in patients may be aggravated by long-term exposure to high doses of antipsychotics76,78.  
 Nonetheless, promoting recovery and course-alteration by (novel) therapies in the critical 
phase after the FEP would certainly be cost-effective37. One important study is RAISE (Recovery 
After Initial Schizophrenia Episode) which proposes a broad suite of treatments, both 
pharmacotherapeutic and other, in order to enhance quality of life, patient function and long-
term outcome. Whether this strategy directly engages with neural substrates underlying 
progression of schizophrenia is unclear, and the lack of a formal “control” group make it hard 
to be sure of the specificity of treatment effects. Nonetheless, preliminary findings are promising, 
this study will be of considerable interest to follow, and has led to enhanced Government 
funding of Early Psychosis programmes265-267.  
For use of course-altering agents after the FEP, there is no dilemma of whom to treat 
compared to CHR subjects who may not convert. Full recovery - sustained functional and 
symptomatic remission - after the FEP is only 10-15%, remission is often incomplete, and relapse is 
common (up to 80 % at 5 years)262,264. Hence, delayed appearance of a second episode, reduced 
symptom intensity and recuperation of real-world function would be suggestive of course-alteration if 
accompanied by structural and other biomarkers of normalised pathophysiology. Success would be 
favoured by well-tolerated medication with high adherence since relapse after the FEP is coupled to 
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non-compliance263. Substance abuse, negative symptoms and poor social functioning suggest a poor 
prognosis so agents that also acted on these symptoms might, by analogy to “hybrid” CHR agents, 
particularly improve long-term outcome (Box 3)8,38,263. 
On the down-side, following the FEP, novel drugs may well have to be given with SGAs so 
differentiating genuine course-alteration versus symptom relief would be difficult263. Moreover, once 
the threshold to psychosis has been transgressed, course-alteration may be harder to achieve owing to 
a network phase-shift and more pronounced structuro-functional changes in the brain170. Finally, 
though adult rescue of behavioural deficits is under study for monogenic forms of autism, the duration 
of relief is uncertain and clinical proof awaited21,26.  
For novel agents, one strategy may be to perform an initial trial with patients in remission after 
a FEP then to “work back in time” to earlier phases, including prevention of conversion in CHR 
subjects. Dose reduction might also be progressively achieved by association with 
psychosocial/cognitive-behvaioural treatments.  
 
Collaborative ventures  promoting discovery and development of course-altering therapies  
Governments, Regulators, Academia, Industry and National Associations are collectively 
searching for solutions to complex and overarching socio-medical challenges like orphan diseases and 
epidemics52,268. One example is the EU Innovative Medicines Initiative “NewMeds” Programme for 
refining the translational tools needed to validate improved treatments for schizophrenia and 
depression268. Another initiative is “PsyScan” which is developing multi-modal strategies for more 
reliably predicting transition in individuals, and which is sufficiently well-powered to deal with 
factors like gender52. Since preventative medicine and adolescent health are now high on the agenda, 
such programmes should accelerate progress towards course-alteration for schizophrenia and other 
psychiatric disorders (Box 2)1-4,17,40,268. Further, prophylactic medicine for cardiovascular and 
inflammatory disorders is widely-accepted. Nevertheless, in light of costs to health services and 
the fact that CHR subjects do not yet have a psychotic diagnosis, it will be important to minimize 
risk and ensure the support of patients, carers, regulators and reimbursers for early 
interventions to prevent transition to schizophrenia, or other psychiatric disorders (Suppl Box 
6). This support should be fostered by: 1), the fact that the great majority of CHR subjects will 
have enduring psychiatric problems (Figure 4); 2) the current focus is on young people that are 
actively seeking help and 3), undertaking initial clinical studies of new drugs in patients who 
have just undergone a FEP (Box 2).  
 
 
General discussion and concluding comments  
 Sustained efforts to improve the symptomatic treatment of schizophrenia have yielded little 
major progress over the past decades. It is important that this work continues within a revised 
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framework focussing on novel mechanisms of action and real-world measures of outcome (Suppl 
Figure 1). However, driven by improved understanding of pathophysiology, there is now scope for a 
complementary strategy that aims to alter the course to and of schizophrenia.  
Much progress is being made in the identification of CHR subjects, and a substantial 
body of clinical and (predominantly) preclinical data converge in suggesting that pre-emptive 
interventions may interrupt (or at least delay) the emergence of a schizophrenia-like phenotype 
(Tables 1 and 2). Evidence from clinical studies is of especial significance though, as emphasized 
above, much remains to be done to confirm promising observations, increase the power and size 
of trials, take account of many complicating variables, and expand studies to novel therapeutic 
mechanisms. The latter enterprise is being driven by cellular studies and work with rodent 
models for schizophrenia. Despite their limitations, a strikingly-broad range of interventions 
administered during adolescence reduces the appearance of schizophrenia-related anomalies in 
adults. Certain treatments, such as those interacting with GABAergic transmission, 
inflammatory processes and the response to stress, have a solid conceptual and experimental 
foundation while others, such as those targeting intracellular proteins, epigenetic marking and 
synaptic pruning require much further characterisation. In any event, recent progress is 
encouraging. 
 Hybrid strategies appear particularly appealing for co-joint relief of symptoms in CHR 
subjects and - partly as a consequence - reduction of transition and improved functional outcome. 
Challenges remain in terms of identifying whom to treat and when best to start treatment, with 
interventions after the FEP an option for drugs as yet untested in humans. Further, only a handful of 
potential approaches have been as yet clinically evaluated, so the issue of how best to treat remains 
unresolved. A one-size-fits-all unitary answer appears improbable and the judicious combination of 
distinct modes of pharmacotherapy and psychosocial/cognitive-behavioural therapy appears the most 
likely route to success. Finally, a crucial issue is how to rapidly predict/demonstrate efficacy over a 
reasonable time-scale in the course of clinical trials. These issues are under intense scrutiny and 
progress should be rapid over the coming years.  
Thus, in addition to improved alleviation of the symptoms of schizophrenia, it may eventually 
become possible to target the underlying pathophysiology and delay, prevent or moderate its progress. 
In view of the huge personal suffering and socio-economic burden of schizophrenia and other 
psychoses, this would seem a worthy goal. 
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Glossary 
Psychosis, a cluster of clinical signs related to, but not identical with, positive symptoms of schizophrenia: 
detachment from reality; compromised insight; hallucinations and delusions; psychomotor anomalies like 
catatonia or agitation; disorganised thought, speech and behaviour. Generally used as the operational definition 
of transition to schizophrenia, despite it’s (less systematic) occurrence in other disorders. 
 
Positive symptoms include delusional thinking, hallucinations, false beliefs, bizarre thoughts, suspiciousness 
and paranoia. While usually mild and transient during the prodrome, full-blown positive symptoms during the 
first episode of psychosis is a diagnostics pillar of schizophrenia. Positive symptoms are reduced in most patients 
by antipsychotics, but remission may be incomplete, relapses occur and about 20-30% of patients are refractory. 
 
Negative symptoms are prominent from the pre-diagnostic to the chronic phase of schizophrenia, poorly 
controlled by antipsychotics and linked to poor real-world function. There are two sub-clusters: 1), decreased 
expression (poverty of speech and blunted affect) and 2), avolition (amotivation, asociality and loss of 
anticipatory pleasure for normally-rewarding activities).  
 
Neurocognitive symptoms, deficits in a broad palette of cognitive domains including those dependent on 
frontocortico-striato and frontocortico-parietal circuits:  attention; working memory (on-line handling of 
information); executive function (planning, decision-making, flexible shifting of goals); speed of processing and 
procedural memory (learning motor tasks); and verbal learning and memory. 
 
Social cognition (processing): processes used to decode social cues, interpret/predict the mental state, beliefs, 
desires and intentions of others, and hence to behave in a socially-appropriate, adaptive manner. Signals include 
facial expression, body posture and hand gestures. Impaired social cognition is seen in the prodrome, interrelated 
with negative symptoms and linked to poor functional outcome. Deficits are irresponsive to antipsychotics. 
 
Disease-modification refers to interventions that directly interrupt, decelerate or even reverse core 
pathophysiological processes causing a disorder with the goal of preventing or delaying its onset, and/or 
moderating its severity once it evolves. Effects should, in principal, persist even after treatment has been 
discontinued, and are not necessarily apparent at the onset of, or even during, administration. 
 
The prodromal phase is a high-risk state which precedes by weeks to years the transition to schizophrenia or 
another psychotic disorder. It is characterised by attenuated and/or brief, self-limiting psychotic symptoms, 
negative, neurocognitive and social cognitive symptoms, depressed mood and other psychological and 
behavioural abnormalities. Not all subjects showing a prodrome convert, so the term is somewhat misleading. 
 
Neurological soft signs refer to a cluster of minor developmental anomalies in motor and sensory integration, 
motor coordination and motor sequencing. They are present in high-risk subjects prior to transition to 
schizophrenia, for which they represent a useful warning sign. 
 
Neurexin-1 is a presynaptically-localized adhesion molecule that interacts with the post-synaptic protein, 
Neuroligin-1. Neurexin 1 is abundant in inhibitory GABAergic synapses where it controls transmitter 
release, as well as synaptic formation and transmission. Neurexin-1 deletions (de novo and inherited) are 
consistently associated with schizophrenia.  
 
Default-mode network: interconnected cerebral regions in humans (including the medial prefrontal cortex, 
cingulate cortex, inferior parietal cortex and precuneus) that are active in fMRI studies under resting conditions: 
for example, during introspection and rumination. Conversely, they are deactivated by goal-directed actions such 
as performance of a working memory test. An equivalent network appears to exist in rodents.  
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Event-Related Potentials: Negative (N) and positive (P) shifts in voltage of EEG recordings triggered by 
external stimuli, usually auditory but also visual. P300 is a positive deflection peaking about 300 msec after a 
deviant (“oddball”) stimulus differing in frequency, duration, strength etc to a previous sequence. Mismatch-
Negativity is a pre-attentional negative response peaking about 100-150 msec after an oddball stimulus. 
 
Machine Learning is a mode of multivariate analysis which uses so-called “Support Vector Machine” 
algorithms to detect otherwise-invisible patterns in large data arrays, and to inter-link the different variables 
recorded. Its application to combined genetic, imaging, clinical and other readouts from high-risk subjects 
increases the sensitivity and specificity of prediction of transition to psychosis, even at the individual level. 
 
Polyunsaturated fatty acids, major components of cell membranes, are derived from dietary linoleic and alpha-
linolenic acid transformed in liver into Omega-6 and Omega-3 derivatives, respectively: numbers refer to 
location of the first double-bond at the methyl end. They are essential for brain function and development 
perinatally and in childhood. Precursor intake is often poor in Western diets and a risk factor for schizophrenia.  
 
Cognitive-Behavioural Therapy is a form of psychotherapy that helps subjects disengage from negative and 
self-defeating thoughts about themselves, their lives and environment and hence to think, feel and behave in a 
more adaptive and positive fashion. It may embrace stress management. Both therapist and computerised modes 
are available for various psychiatric disorders, including people at high risk of developing schizophrenia. 
 
Minocycline is a tetracycline-like antibiotic with anti-inflammatory and anti-oxidant properties which easily 
enters the brain. It is under investigation for a number of CNS disorders, including adjunctive therapy with 
antipsychotics for the treatment of schizophrenia, especially negative symptoms soon after diagnosis. 
 
N-Acetyl-Cysteine is an analogue of L-Cysteine which is rapidly oxidised into Cystine in the brain. Cystine is a 
substrate of glial Cystine-Glutamate antiporters, so N-Acetyl-Cysteine elevates extracellular levels of glutamate. 
In cells, Cystine is reduced into Cysteine, the rate-limiting component of the anti-oxidant, Glutathione. Hence, 
N-Acetyl-Cysteine enhances Glutathione activity. N-Acetyl-Cysteine also exerts anti-inflammatory properties. 
 
Kalirin-7 is a member of a family of brain-specific guanine-nucleotide exchange factors for Rac-like GTPases 
like Rac-1. Kalarin-7 is located in the post-synaptic density, where it interacts with the actin cytoskeleton to  
regulate the formation, maturation and stability of dendritic spines, and hence influence synaptic plasticity. 
 
A subset of fast-firing (frequency, 40-1,000hz), parvalbumin-positive basket (and chandelier) GABAergic 
interneurons in PFC synchronises the activity of local, intra-cortical and cortico-subcortical networks of 
glutamatergic pyramidal neurones. Their dysfunction, which leads to a disruption of excitation-inhibition 
balance, network synchrony, cognition and mood, is implicated in events leading to schizophrenia.  
 
The extracellular matrix contains proteins like astrocyte-derived chondroitin sulphate proteoglycans, 
hyaluronans, Neuregulins and Reelin. It fills the space between cells in the brain, including the synaptic cleft. 
“Peri-neuronal nets” appear post-natally, are localised  peri-synaptically, and stabilize neural connections. Their 
developmental disruption has been related to abnormal plasticity and the genesis of schizophrenia. 
 
Graph theory: mathematical analysis of networks of proteins, cells, brain regions and individuals in social 
groups. Elements are considered nodes connected by edges (vectors). Brain organisation is modular and non-
random incorporating features that enhance integration like highly-connected hubs and short path length between 
nodes (“small world”). In schizophrenia, this organisation is disrupted. 
 
The Na-K-Cl co-transporter transports Chloride (Cl-) into neurones: two atoms of Cl- plus one each of N+ and 
K+. Accumulation of excess Cl- is prevented by extrusion via the co-transporter “KCC2”.  In early life, NKCC1 
levels are elevated vs KCC2 so internal Cl- increases and GABA-A receptors mediate depolarisation not 
hyperpolarisation. Owing to lack of a developmental switch, this may persist in autism and schizophrenia. 
 
Reelin is a developmentally-regulated Glycoprotein that controls neuronal migration, corticogenesis and 
synaptic plasticity. Reelin is enriched in and secreted by GABAergic interneurons in adult PFC where it is co-
regulated with GABA by epigenetic mechanisms. It is a component of the extracellular matrix. 
 
MicroRNAs are short, ca 22-24 nucleotide long stretches of protein non-coding RNA that neutralize and 
destabilize matching mRNAs (up to hundreds of different ones): where the match is perfect, mRNA is degraded. 
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Hundreds of different species of miRNAs exist in the brain. Many interact with developmentally-important 
proteins, and cerebral levels of diverse classes of miRNA are altered in schizophrenia.  
 
Human endogenous retroviruses encode a protein envelope, reverse transcriptase and other proteins needed for 
replication. They are relics of ancient infections that survived by integration into the genome where multiple 
copies occur due to amplification and re-infection. They comprise about 8-10 % of the human genome, mostly in 
protein non-coding regions. Revival may trigger disorders like multiple sclerosis and, possibly, schizophrenia. 
 
Synaptic pruning, processes for developmental elimination of “excess” synaptic connections especially 
prominent during adolescence. Axo-dendritic synapses not stabilized by neural activity in frontocortical, 
temporocortical and hippocampal regions are especially impacted. Appropriate synaptic pruning optimizes the 
operation of neural networks, while both excessive (schizophrenia) and defective (autism) pruning is deleterious.  
 
RAISE is a National Institute of Mental Health Initiative to alter the course and prognosis of FEP. A well-
trained, multidisciplinary team offers (up to two years) pharmacotherapeutic and psychosocial treatments 
together with family education, resiliency training and supported employment in a patient-centric and 
real-world fashion to improve function and promote recovery. 
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Figure 1 Onset and progression of schizophrenia in relation to risk factors and developmental 
processes impacted by the disorder. 
Figure 1A. The diagnosis of schizophrenia operationally corresponds to the first full psychotic 
episode (“FEP”), is usually made in young adults, but can (rarely) occur in childhood, adolescence or 
later in life. Diagnosis generally follows a “prodromal”, at-risk phase in which sub-threshold psychotic 
episodes and other characteristic symptoms are apparent. Once diagnosed, schizophrenia follows a 
fluctuating course punctuated by acute exacerbation of psychotic crises superimposed upon a 
background of poorly-controlled negative, neurocognitive and social cognitive symptoms. About 10-
15% of patients recover after their FEP, while a similar proportion display a more severe and 
unremitting form of the disorder. In addition to inheritance (Suppl Box 1), many environmental risk 
factors have been incriminated both during both the peri-natal (first wave) period and during 
adolescence. Genetic and environmental impacts at least partially act via epigenetic misprogramming 
of neurodevelopment. Throughout the disorder, adverse environmental events can trigger crises. 
Figure 1B. The course to and progression of schizophrenia can be related to three fundamental phases 
in the “life” of the brain - though depicted sequentially they are interlinked and there is no absolute 
demarcation. Each phase is anomalous in schizophrenia, with disruption of brain formation and 
(re)organisation implicated in causal pathophysiology. Both of these phases, as well as brain 
“upkeep”, embrace a spectrum of processes potentially available for therapeutic intervention. Pre and 
post-diagnostic course-altering interventions are conveniently labelled “prevention” and “reversal”, 
respectively, but only relative to the clinical picture: underlying pathophysiological changes will have 
set in much earlier. Currently, the most compelling “Window of Opportunity” is around the first 
episode to impede onset, or block early progression. 
 
Figure 2 Course-alteration and disease-modification: core facets. 
The notion of disease-modification, more familiar for neurodegenerative disorders, refers to a 
direct and enduring impact on the disease process: that is, on causal pathophysiological mechanisms. 
This leads to a delay or halting of the onset or progression of the disorder. Neurobiological substrates 
of schizophrenia are incompletely defined, multiple and, at least to some extent, symptom-specific. 
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Further, causal processes are subject to modulatory neural influences so a more liberal interpretation of 
disease-modification incorporates agents that respectively block or promote processes favouring or 
hindering disease evolution. This notion can be integrated into the more general concept of course-
alteration. In addition, precocious relief of certain classes of symptom (like impaired social cognition) 
and countering risk factors (like drug-seeking behaviour and “stress”) may slow the path to 
schizophrenia (Suppl Figures 2 and 3). While “prevention” and “rescue” are relative to diagnosis, the 
pathophysiological road to schizophrenia is enacted far earlier (Figure 1).  
Figure 3 Clinical trajectories of help-seeking young subjects at high risk for developing 
schizophrenia: diverse strategies for their detection.  
Figure 3A. Amongst CHR people seeking help, many will need treatment for psychiatric 
problems like depression, anxiety and even sub-diagnostic psychotic episodes. Based on observations 
in specialized centres (Box 2), about a third convert to schizophrenia or another psychosis within 2-5 
years. A minority will remit, some will remain in a comparable state of impairment, while others will 
transit to another psychiatric disorder - not necessarily associated with psychosis. This emphasizes the 
importance of trans-nosological thinking for strategies designed to reduce conversion. The values 
shown are based on a study performed (1993-2006) in a specialised Australian clinic of a CHR 
sample45.  Figure 3B. Comprehensive clinical assessment is crucial for identifying CHR subjects, 
especially when coupled to information on life-style like recreational drug abuse and social isolation. 
A broad palette of measures are also instructive for predicting conversion, though no single measure 
alone has adequate fidelity for reliably predicting the fate of individuals. Multi-modal strategies help 
enhance sensitivity and specificity of predictions, even at the individual level, and are useful for 
stratification of subgroups. Abbreviations not in text: EEG; Electroencephalography; MRS, Magnetic 
Resonance Spectroscopy and PET, Positron Emission Tomography. 
 
Figure 4 Overview of core pathophysiological mechanisms implicated in the genesis of 
schizophrenia: potential targets for course-altering intervention.  
 Figure 4A. Several, potentially-targetable mechanisms are incriminated in the genesis of 
schizophrenia. The antipsychotic-sensitive hyperactivity of subcortical dopaminergic projections is a 
comparatively late repercussion of other (upstream) pathophysiological events, and the high-risk phase 
is characterised by several anomalies like disruption of cortisol secretion, perturbed activity of several 
classes of neurotransmitter and, probably, anomalous pruning of synapses.  Anticipating such changes 
is a disruption of GABAergic-glutamatergic networks in corticolimbic regions, including a 
hypoactivity of NMDA receptors on GABAergic interneurons. Even earlier, cellular modulators of 
neural differentiation, migration and plasticity are deregulated.  Finally, three other global mechanisms 
playing a role in the genesis of schizophrenia are indicated: neuroinflammation, epigenetic 
misprogramming and aberrant patterns of cortical myelination. Figure 4B. Anomalies are apparent at 
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several interacting levels of regulation, from molecules to cells to cerebral circuits to social networks. 
All present opportunities for intervention and, though drugs engage with molecular targets, they 
influence higher echelons of this hierarchy. G-protein coupled receptors and ion channels (not shown) 
are relevant at all levels. Epigenetic mechanisms exert a broad-based influence upon networks of 
proteins. Mitigation of “stress” would have multifarious, beneficial effects in protecting circuits from 
disruption.  Agents that normalise GABAergic interneuron activity should re-coordinate perturbed 
cortico-subcortical networks controlling mood and cognition. Protecting oligodendrocyes may 
reconfigure neural networks where myelin has been damaged by inflammation or other insults. Axons 
themselves are disrupted in schizophrenia, so promoting their structural and functional integrity would 
be of interest. Agents acting in the PFC to favour top-down control of neurocognition and social 
function could be effective, while CBT and stimulation techniques engage widespread cortical circuits. 
Drug associations and multi-target drugs with complementary mechanisms of action may also  be 
especially effective for network reconstitution and course-alteration. ErbB is a tyrosine receptor kinase 
receptor. Abbreviations not in text: CRT; cognitive-remediation therapy; Glu, glutamate; mTOR; 
mammalian target of rapamycin; NCAM, Neural cell adhesion molecule; rTMS, rapid transcranial 
magnetic stimulation and DCS, direct current stimulation.  
 
Figure 5 Schematic representation of a “hybrid” strategy as compared to other therapeutic 
approaches for treating schizophrenia and its genesis. 
 Currently, we are limited to symptomatic control of schizophrenia. However, treatment needs 
to be improved, in particular as regards resistant patients and symptoms other than positive (Suppl 
Figure 1). Early-life, “disease-modifying” medication to interrupt the path to schizophrenia presents 
formidable problems of validation, clinical development and safety. Accordingly, therapeutic 
exploitation is not yet a viable proposition. Nonetheless, one pragmatic strategy would be to target the 
pathophysiology and symptoms presented by CHR help-seeking, young people. For example, 
palliating stress-induced HPA axis overdrive and promoting social cognition both alleviate symptoms 
and, at least partly as a consequence, may reduce the risk of conversion (Suppl Figure 3). Inasmuch as 
certain pre-diagnostic symptoms and neurobiological substrates are not unique to schizophrenia, the 
transition to other psychiatric disorders may likewise be impeded. A dual, “hybrid” strategy would 
have advantages in terms of developability and therapeutic utility over pure course-alteration (see 
text).  
